Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.
The company possesses a narrow moat driven by its global innovative medicine portfolio and dominant scale in the Indian branded generics market. This is corroborated by high gross margins exceeding 80% and a consistent ability to outpace industry volume growth despite regulatory headwinds in the US generics segment.
Management has demonstrated a disciplined shift from commoditized generics toward high-value innovative medicines, funded by strong internal cash flows. Recent major deployments include the $11.75 billion Organon acquisition and the Checkpoint Therapeutics buyout, aimed at building a global specialty platform in dermatology and oncology.
The specialty medicine pivot collapsed under the weight of its own complexity. While management chased high-margin dermatology and oncology assets, the core manufacturing engine stalled as the US FDA escalated import alerts from Halol to the entire domestic supply chain, choking off the cash flow needed to service the debt from the Organon and Checkpoint acquisitions. The specialty portfolio failed to achieve the necessary scale to offset the erosion of the legacy generics business, and the high intangible asset base was eventually written down, leaving the company with a bloated balance sheet and a broken reputation for quality.
RichFakir rates Sun Pharmaceutical Industries Ltd's business quality as wonderful — 71/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Sun Pharmaceutical Industries Ltd is trading about 68% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sun Pharmaceutical Industries Ltd is: Watch — wait for price. A wonderful business, but at an expensive price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of Sun Pharmaceutical Industries Ltd's fair value is about ₹1,055 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →